2
项与 Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) 相关的临床试验Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
100 项与 Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) 相关的临床结果
100 项与 Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) 相关的转化医学
100 项与 Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) 相关的专利(医药)
100 项与 Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) 相关的药物交易